Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity.
Santisteban
M
M
Departamento de Oncología Médica, Clínica Universitaria de Navarra, Pamplona, Spain. msantisteb@unav.es
Nieto
Y
Y
De la Cruz
S
S
Aristu
J
J
Zubieta
J L
JL
Fernández Hidalgo
O
O
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001921:Brain / Q000000981:diagnostic imaging; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015182:Lymphatic Irradiation; D008223:Lymphoma / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011859:Radiography; D000069283:Rituximab; D000077204:Temozolomide
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D003606:Dacarbazine; D000077204:Temozolomide